Skip to main content
VulnerabilityPublished Updated

CVE-2026-14959: IBM Aspera Faspex 5 · OS Command Injection

Affects IBM Aspera Faspex 5Source CVE Database V5

0

Not known to be exploited · CVSS 9.1 Critical.

Data as of 26 Oct 2026, 17:16 UTC

CVSS 3.1 base score
9.1Critical
How severe the flaw is on the 0–10 CVSS scale.
EPSS
1.5% chance of exploitation in 30 days – higher than 74% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 28 Jul 2026

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 26 Oct 2026.

What to do

Affected software

ProductAffectedFixed in
IBMAspera Faspex 5Affected
  • >=5.0.0 <=5.0.15.4
Fixed in–

CPE configurations (2)

  • cpe:2.3:a:ibm:aspera_faspex_5:5.0.0:*:*:*:*:*:*:*
  • cpe:2.3:a:ibm:aspera_faspex_5:5.0.15.4:*:*:*:*:*:*:*

AI-suggested

Until an official fix is available, restrict access to the affected versions and monitor for suspicious activity. Do not rely on generic mitigations as this vulnerability requires specific patching once available.

Description

IBM Aspera Faspex 5 versions 5.0.0 through 5.0.15.4 contain a critical OS command injection vulnerability that allows a remote authenticated attacker to execute arbitrary code via shell command injection. This vulnerability is identified as CWE-78 and has a CVSS 3.1 score of 9.1, indicating high impact on confidentiality, integrity, and availability.

References

Community reviews

Loading reviews…